Glucosylceramidase Beta (GBA) Genotyping

Research Community
Research Community

ASAP supports three programs and serves as a member of multiple consortia to advance research for the benefit of the global Parkinson’s disease community.
Explore
Highlights
Highlights

ASAP shares the impact that our initiative, network, and supported programs have had on providing new insights into Parkinson’s disease. Discover news, interviews, awards, and annual impact.
Explore
Open Science
Open Science

ASAP is dedicated to facilitating a research environment where meaningful collaboration, research-enabling resources, and data sharing provides the answers we need to understand, diagnose, and treat Parkinson’s disease. Discover our open science philosophy.
Explore
Tools & Resources
Tools & Resources

ASAP is committed to developing and openly sharing research outputs, including data, code, protocols, and key lab materials, to help the scientific community build upon existing work.
Explore

Description

This protocol details the steps for GBA genotyping. This protocol has been adapted from the PRoBaND Clinical Consortium (incorporating methods described by Neuman et al., 2009 and Stone et al., 2000) and has been used for all publications for PRoBaND / Tracking Parkinson's describing clinical data and outcomes with respect to GBA status

Identifier (DOI)

10.17504/protocols.io.bzd7p29n

Tags

GBA (Glucocerebrosidase)
Genotyping
PCR
Sequencing

Team

Team Hardy

Program

Collaborative Research Network

Theme

PD Functional Genomics

Meet the Authors

Huw Morris

Collaborating PI: Team Hardy,

University College London

Glucosylceramidase Beta (GBA) Genotyping

Output Details

Meet the Authors

Huw Morris

Related Research

The GBA variant E326K is associated with alpha-synuclein aggregation and lipid droplet accumulation in human cell lines

Early deficits in an in vitro striatal microcircuit model carrying the Parkinson’s GBA-N370S mutation

Targeting the GBA1 pathway to slow Parkinson disease: Insights into clinical aspects, pathogenic mechanisms and new therapeutic avenues